Animal models for autoimmune hepatitis

Autoimmunity Reviews

Volumn 6, Issue 5, 2007, Pages 306-311

  Christen, Urs ^a,b   Holdener, Martin ^a,b   Hintermann, Edith ^a  

^a GOETHE UNIVERSITY   (Germany)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Adenovirus; Autoimmune liver disease; Molecular mimicry; Tolerance; Virus infection

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; CYTOCHROME P450 2D6; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FIBROSIS; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SYNDROME DELINEATION;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MICE; MODELS, IMMUNOLOGICAL;

EID: 33947717115     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.04.001     Document Type: Review

References (40)

1. Manns M.P. Recent developments in autoimmune liver diseases. J Gastroenterol Hepatol 12 (1997) S256-S271
2. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 334 (1996) 897-903
3. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
4. Czaja A.J., and Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105 (1993) 1824-1832
5. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., and Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33 (1998) 99-103
6. Milkiewicz P., Hubscher S.G., Skiba G., Hathaway M., and Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68 (1999) 253-256
7. Wiesner R.H., Demetris A.J., Belle S.H., Seaberg E.C., Lake J.R., Zetterman R.K., et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (1998) 638-645
8. Czaja A.J., dos Santos R.M., Porto A., Santrach P.J., and Moore S.B. Immune phenotype of chronic liver disease. Dig Dis Sci 43 (1998) 2149-2155
9. Czaja A.J., and Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36 (2002) 479-497
10. Poralla T., Treichel U., Lohr H., and Fleischer B. The asialoglycoprotein receptor as target structure in autoimmune liver diseases. Semin Liver Dis 11 (1991) 215-222
11. Manns M.P., and Strassburg C.P. Autoimmune hepatitis: clinical challenges. Gastroenterology 120 (2001) 1502-1517
12. Manns M.P., Johnson E.F., Griffin K.J., Tan E.M., and Sullivan K.F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83 (1989) 1066-1072
13. Zanger U.M., Hauri H.P., Loeper J., Homberg J.C., and Meyer U.A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci U S A 85 (1988) 8256-8260
14. Yamamoto A.M., Cresteil D., Boniface O., Clerc F.F., and Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 23 (1993) 1105-1111
15. Manns M.P., Griffin K.J., Sullivan K.F., and Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88 (1991) 1370-1378
16. Kitazawa E., Igarashi T., Kawaguchi N., Matsushima H., Kawashima Y., Hankins R.W., et al. Differences in Anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and-positive Patients. J Autoimmun 17 (2001) 243-249
17. Lohr H., Manns M., Kyriatsoulis A., Lohse A.W., Trautwein C., Meyer zum Buschenfelde K.H., et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 84 (1991) 297-302
18. Czaja A.J., Carpenter H.A., Santrach P.J., and Moore S.B. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105 (1993) 1502-1507
19. Doherty D.G., Donaldson P.T., Underhill J.A., Farrant J.M., Duthie A., Mieli-Vergani G., et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19 (1994) 609-615
20. Lenzi M., Ballardini G., Fusconi M., Cassani F., Selleri L., Volta U., et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 335 (1990) 258-259
21. Miyakawa H., Kitazawa E., Kikuchi K., Fujikawa H., Kawaguchi N., Abe K., et al. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C. Autoimmunity 33 (2001) 23-32
22. Kammer A.R., van der Burg S.H., Grabscheid B., Hunziker I.P., Kwappenberg K.M., Reichen J., et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 190 (1999) 169-176
23. Oldstone M.B.A. Molecular mimicry and autoimmune disease. Cell 50 (1987) 819-820
24. Christen U., Jenö P., and Gut J. Halothane metabolism: The dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 32 (1993) 1492-1499
25. 3CO-lysine by lipoic acid. Eur J Biochem 223 (1994) 1035-1047
26. Gershwin M.E., Ansari A.A., Mackay I.R., Nakanuma Y., Nishio A., Rowley M.J., et al. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 174 (2000) 210-225
27. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38 (2003) 1250-1257
28. Delovitch T.L., and Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7 (1997) 727-738
29. Amoh Y., Yasumizu R., Yamamoto Y., Toki J., Nishio N., Adachi Y., et al. The appearance of unusual phenotypic cells (CD4+ Mac-1+ class II+) in the liver of (NZW × BXSB)F1 mice is possibly an animal model for autoimmune hepatitis. Immunobiology 197 (1997) 31-43
30. Ando K., Guidotti L.G., Wirth S., Ishikawa T., Missale G., Moriyama T., et al. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 152 (1994) 3245-3253
31. Moriyama T., Guilhot S., Klopchin K., Moss B., Pinkert C.A., Palmiter R.D., et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248 (1990) 361-364
32. Limmer A., Sacher T., Alferink J., Kretschmar M., Schonrich G., Nichterlein T., et al. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 28 (1998) 2395-2406
33. Sacher T., Knolle P., Nichterlein T., Arnold B., Hammerling G.J., and Limmer A. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur J Immunol 32 (2002) 3628-3637
34. Voehringer D., Blaser C., Grawitz A.B., Chisari F.V., Buerki K., and Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 165 (2000) 2415-2422
35. Oldstone M.B.A., Nerenberg M., Southern P., Price J., and Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65 (1991) 319-331
36. Djilali-Saiah I., Lapierre P., Vittozi S., and Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol 169 (2002) 4889-4896
37. Lapierre P., Djilali-Saiah I., Vitozzi S., and Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 39 (2004) 1066-1074
38. Christen U., and von Herrath M.G. Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model. Transgenic Res 11 (2002) 587-595
39. Corchero J., Granvil C.P., Akiyama T.E., Hayhurst G.P., Pimprale S., Feigenbaum L., et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60 (2001) 1260-1267
40. Holdener M, Hintermann A, Rhode A, Wolfe T, Gonzalez FJ, Johnson EF, Manns M, von Herrath MG, Christen U. A novel model for human autoimmune hepatitis: Breaking tolerance to human CYP2D6 by viral infection. (Manuscript) (submitted for publication).